Barclays Forecasts Strong Price Appreciation for Protagonist Therapeutics (NASDAQ:PTGX) Stock

Protagonist Therapeutics (NASDAQ:PTGX) had its price target upped by stock analysts at Barclays from $113.00 to $119.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price target points to a potential upside of 20.36% from the stock’s current price.

A number of other analysts have also recently commented on PTGX. Weiss Ratings cut shares of Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, February 17th. TD Cowen lifted their price objective on Protagonist Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Citizens Jmp boosted their price objective on Protagonist Therapeutics from $102.00 to $112.00 and gave the company a “market outperform” rating in a research note on Thursday, February 26th. HC Wainwright upped their target price on Protagonist Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Finally, Citigroup raised their target price on Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $107.31.

Protagonist Therapeutics Stock Performance

Shares of NASDAQ PTGX opened at $98.87 on Thursday. The company’s 50 day moving average price is $87.17 and its 200-day moving average price is $80.87. Protagonist Therapeutics has a 52-week low of $39.60 and a 52-week high of $105.69. The company has a market capitalization of $6.31 billion, a P/E ratio of -48.23 and a beta of 2.23.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.16). Protagonist Therapeutics had a negative return on equity of 19.89% and a negative net margin of 282.83%.The firm had revenue of $7.44 million for the quarter, compared to analyst estimates of $14.92 million. Analysts forecast that Protagonist Therapeutics will post 2.43 earnings per share for the current year.

Insider Activity

In other news, Director Lewis T. Williams sold 18,000 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $82.42, for a total transaction of $1,483,560.00. Following the transaction, the director owned 7,825 shares of the company’s stock, valued at $644,936.50. This represents a 69.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director William D. Waddill sold 20,000 shares of the firm’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $83.68, for a total value of $1,673,600.00. Following the completion of the sale, the director owned 7,825 shares of the company’s stock, valued at approximately $654,796. This represents a 71.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 203,167 shares of company stock valued at $16,889,199. Corporate insiders own 4.90% of the company’s stock.

Institutional Investors Weigh In On Protagonist Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Rockefeller Capital Management L.P. increased its holdings in shares of Protagonist Therapeutics by 10.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 3,292 shares of the company’s stock valued at $288,000 after acquiring an additional 312 shares in the last quarter. Seven Fleet Capital Management LP bought a new position in shares of Protagonist Therapeutics in the 4th quarter worth $699,000. Invesco Ltd. grew its position in Protagonist Therapeutics by 56.2% in the 4th quarter. Invesco Ltd. now owns 1,567,840 shares of the company’s stock valued at $136,935,000 after purchasing an additional 564,134 shares during the period. KVP Capital Advisors LP bought a new stake in Protagonist Therapeutics during the 4th quarter valued at $4,629,000. Finally, Virtus Investment Advisers LLC increased its stake in Protagonist Therapeutics by 38.1% during the 4th quarter. Virtus Investment Advisers LLC now owns 2,790 shares of the company’s stock valued at $244,000 after purchasing an additional 770 shares in the last quarter. Institutional investors own 98.63% of the company’s stock.

More Protagonist Therapeutics News

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: FDA approval of J&J’s Icotyde for plaque psoriasis materially improves Protagonist’s near-term commercial outlook by triggering milestone payments and future royalty upside tied to Protagonist’s partnered program. Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here’s Why
• Positive Sentiment: Market reaction: coverage highlights a ~6–7% lift tied to the approval and notes the path to royalties; higher-than-average volume suggests institutional interest and re-rating momentum. Why Protagonist Therapeutics (PTGX) Is Up 6.6% After First Psoriasis Drug Wins FDA Approval
• Positive Sentiment: Several major banks raised price targets and reiterated buy/overweight ratings following the approval, providing further upside expectations (Leerink, JPMorgan, Citigroup, Barclays). These analyst upgrades are supporting the stock’s recent run. Analyst coverage roundup (Benzinga) JPMorgan note (TickerReport) Citigroup coverage (Zacks)
• Positive Sentiment: Zacks notes recent momentum and that recent earnings-estimate revisions could support further upside in the near term. Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?
• Neutral Sentiment: Broader Wall Street commentary emphasizes that J&J’s approval should create “significant value” for Protagonist, reinforcing sentiment but not guaranteeing cash flow until milestones/royalties are realized. Wall Street says J&J’s FDA-approved psoriasis drug should create significant value for Protagonist
• Negative Sentiment: Key risk: Protagonist reported an earnings and revenue miss in its last report and remains unprofitable with negative margins—meaning the market is pricing future milestone/royalty potential rather than current cash generation. This raises execution and timing risk (milestones may be delayed or smaller than expected).

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.